Tumor scatter and the invisible margin

Diseases of the Colon and Rectum

Volumn 55, Issue 12, 2012, Pages 1203-1205

  Steele, Scott R ^a  

^a MADIGAN ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT CHEMORADIOTHERAPY; CANCER CELL; CANCER PROGNOSIS; CANCER SURGERY; DISEASE FREE SURVIVAL; EDITORIAL; HUMAN; LYMPH VESSEL METASTASIS; METASTASIS; OVERALL SURVIVAL; TREATMENT RESPONSE;

FEMALE; HUMANS; MALE; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; RECTAL NEOPLASMS;

EID: 84872245533     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1097/DCR.0b013e31826f609a     Document Type: Editorial

References (14)

1. Ruo L, Tickoo S, Klimstra DS, et al. Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg. 2002;236:75-81.
2. Heald RJ, Moran BJ, Ryall RD, Sexton R, MacFarlane JK. Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997. Arch Surg. 1998;133:894-899.
3. Moore HG, Riedel E, Minsky BD, et al. Adequacy of 1-cm distal margin after restorative rectal cancer resection with sharp mesorectal excision and preoperative combined-modality therapy. Ann Surg Oncol. 2003;10:80-85.
4. Sauer R, Becker H, Hohenberger W, et al; German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiother apy for rectal cancer. N Eng l J Me d. 2004;351:1731-1740.
5. Garcia-Aguilar J, Chen Z, Smith DD, et al. Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer. Ann Surg. 2011;254:486-492.
6. Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240:711-717.
7. Kundel Y, Brenner R, Purim O, et al. Is local excision after complete pathological response to neoadjuvant chemoradiation for rectal cancer an acceptable treatment option? Dis Colon Rectum. 2010;53:1624-1631.
8. Tulchinsky H, Rabau M, Shacham-Shemueli E, et al. Can rectal cancers with pathologic T0 after neoadjuvant chemoradiation (ypT0) be treated by transanal excision alone? Ann Surg Oncol. 2006;13:347-352.
9. Nair RM, Siegel EM, Chen DT, et al. Long-term results of transanal excision after neoadjuvant chemoradiation for T2 and T3 adenocarcinomas of the rectum. J Gastrointest Surg. 2008;12:1797-1805.
10. Jörgren F, Johansson R, Damber L, Lindmark G. Risk factors of rectal cancer local recurrence: population-based survey and validation of the Swedish rectal cancer registry. Colorectal Dis. 2010;12:977-986.
11. Law WL, Chu KW. Anterior resection for rectal cancer with me-sorectal excision: a prospective evaluation of 622 patients. Ann Surg. 2004;240:260-268.
12. Mezhir JJ, Shia J, Riedel E, et al. Whole-mount pathologic analysis of rectal cancer following neoadjuvant therapy: implications of margin status on long-term oncologic outcome. Ann Surg. 2012;256:274-279.
13. Fitzgerald TL, Brinkley J, Zervos EE. Pushing the envelope beyond a centimeter in rectal cancer: oncologic implications of close, but negative margins. J Am Coll Surg. 2011;213:589-595.
14. Hiotis S P, Weber SM, Cohen AM, et al. Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients. J Am Coll Surg. 2002;194:131-135.